CD276 overexpression	Solid Tumor	CD276 overexpression	Solid Tumor	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Prostate Cancer	CD276 overexpression	Prostate Cancer	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Small Cell Lung Cancer	CD276 overexpression	Small Cell Lung Cancer	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Non Small Cell Lung Cancer	CD276 overexpression	Non Small Cell Lung Cancer	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Esophageal Squamous Cell Carcinoma	CD276 overexpression	Esophageal Squamous Cell Carcinoma	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 expression	Head and Neck Cancer	CD276 expression	Head and Neck Cancer	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D
CD276 expression	Breast Cancer	CD276 expression	Breast Cancer	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D
CD276 expression	Neuroblastoma	CD276 expression	Neuroblastoma	B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical B7-H3-targeted antibody-drug conjugate Sensitive : D	B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical B7-H3-targeted antibody-drug conjugate Sensitive : D
CD276 expression	Pancreatic Ductal Adenocarcinoma	CD276 expression	Pancreatic Ductal Adenocarcinoma	B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical B7-H3-targeted antibody-drug conjugate Sensitive : D	B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical B7-H3-targeted antibody-drug conjugate Sensitive : D
CD276 overexpression	Squamous Cell Carcinoma of Head and Neck	CD276 overexpression	Squamous Cell Carcinoma of Head and Neck	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D
CD276 overexpression	Triple Negative Breast Cancer	CD276 overexpression	Triple Negative Breast Cancer	B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical B7-H3-targeted antibody-drug conjugate Sensitive : D	B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical B7-H3-targeted antibody-drug conjugate Sensitive : D
CD276 expression	Prostate Cancer	CD276 expression	Prostate Cancer	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D
CD276 overexpression	Breast Cancer	CD276 overexpression	Breast Cancer	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D
CD276 overexpression	Lung Cancer	CD276 overexpression	Lung Cancer	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D
CD276 expression	Neuroblastoma	CD276 expression	Neuroblastoma	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D

B7-H3-targeted antibody-drug conjugate

B7-H3-targeted antibody-drug conjugate

Associations(15)

Associations
(15)